Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CTPI-2 是一种特异性线粒体柠檬酸盐载体SLC25A1抑制剂,KD=3.5 μM,具有抗肿瘤作用。它能够抑制糖酵解、PPARγ 及其下游靶点葡萄糖转运蛋白 GLUT4。它阻断非酒精性脂肪性肝炎逆转脂肪变性的显著改变,防止演变为脂肪性肝炎,减少肝脏和脂肪组织中炎性巨噬细胞的浸润,并显著减轻由高脂肪饮食引起的肥胖。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 332 | 现货 | ||
50 mg | ¥ 467 | 现货 | ||
100 mg | ¥ 671 | 现货 | ||
500 mg | ¥ 1,896 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 195 | 现货 |
产品描述 | CTPI-2 is an inhibitor of mitochondrial citrate carrier SLC25A1 with(KD : 3.5 μM). CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 exhibits anti-tumor activity.CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. |
靶点活性 | SLC25A1:3.5 μM (KD) |
体内活性 | CTPI-2, halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, while starkly mitigating obesity induced by a high-fat diet.?These effects are differentially recapitulated by a global ablation of one copy of the Slc25a1 gene or by a liver-targeted Slc25a1 knockout, which unravel dose-dependent and tissue-specific functions of this protein.?Mechanistically, through citrate-dependent activities, Slc25a1 inhibition rewires the lipogenic program, blunts signaling from peroxisome proliferator-activated receptor gamma, a key regulator of glucose and lipid metabolism, and inhibits the expression of gluconeogenic genes.?The combination of these activities leads not only to inhibition of lipid anabolic processes, but also to a normalization of hyperglycemia and glucose intolerance as well[1]. |
分子量 | 356.74 |
分子式 | C13H9ClN2O6S |
CAS No. | 68003-38-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (84.1 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8032 mL | 14.0158 mL | 28.0316 mL | 70.079 mL |
5 mM | 0.5606 mL | 2.8032 mL | 5.6063 mL | 14.0158 mL | |
10 mM | 0.2803 mL | 1.4016 mL | 2.8032 mL | 7.0079 mL | |
20 mM | 0.1402 mL | 0.7008 mL | 1.4016 mL | 3.504 mL | |
50 mM | 0.0561 mL | 0.2803 mL | 0.5606 mL | 1.4016 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CTPI-2 68003-38-3 Metabolism Others Mitochondrial Metabolism macrophage carrier NSCLC transporter CTPI2 glucose steatohepatitis steatosis inflammatory CTPI 2 inhibit citrate Inhibitor mitochondrial inhibitor